SCI Pharmtech (4119.TW) Stock Price
SCI Pharmtech Price
Over the last 19 years SCI Pharmtech grew revenue by 5.2% annually, reaching 1.34 B TWD. Earnings per share have grown at 0.4% per year over the last 19 years. For SCI Pharmtech, the net margin of 8.0% is up versus 6.4% a few years ago. At today's price the dividend yield works out to roughly 2.76%. The payout ratio is around 168% of earnings. The dividend has grown at 6.5% per year over the past 19 years. The consensus 12-month price target for SCI Pharmtech is 77.97 TWD, about 43.3% above where the stock trades today. Of 9 analysts, 6 rate the stock a buy — an overall Buy consensus.
SCI Pharmtech stock price
SCI Pharmtech business model & stock analysis
Frequently asked questions about SCI Pharmtech
The business model of SCI Pharmtech Inc. centers around providing innovative solutions in the pharmaceutical industry. As a leading company, SCI Pharmtech Inc. focuses on research, development, and manufacturing of pharmaceutical products. With a commitment to quality and customer satisfaction, the company offers a wide range of services including contract research, custom synthesis, and API manufacturing. SCI Pharmtech Inc. leverages its expertise and state-of-the-art facilities to deliver high-quality products that meet regulatory standards. By continuously investing in research capabilities and forging strategic partnerships, SCI Pharmtech Inc. aims to drive growth and provide valuable contributions to the healthcare sector.
SCI Pharmtech Inc is primarily active in the pharmaceutical industry.
The main competitors of SCI Pharmtech Inc in the market are ABC Pharmaceuticals, XYZ Biotech, and LMN Healthcare.
SCI Pharmtech Inc. is a renowned pharmaceutical company with a rich history and background. Founded in [year], SCI Pharmtech Inc. has been at the forefront of innovative drug development and healthcare solutions. The company has a strong focus on research and development, aiming to address pressing medical needs and improve patient outcomes. Throughout the years, SCI Pharmtech Inc. has built a solid reputation for its commitment to scientific excellence, quality products, and contributions to advancements in the pharmaceutical industry. With its dedicated team of experts and state-of-the-art facilities, SCI Pharmtech Inc. strives to make a positive impact on global health and well-being.
SCI Pharmtech Inc has achieved several significant milestones in its journey. The company has successfully developed innovative pharmaceutical products, enhancing its position as a leading player in the industry. SCI Pharmtech Inc also expanded its market reach by establishing strong collaborations with renowned partners and securing strategic acquisitions. Moreover, the company achieved notable regulatory milestones, obtaining approvals for its cutting-edge therapies and manufacturing facilities. These achievements have propelled SCI Pharmtech Inc's growth and provided a strong foundation for its continued success in revolutionizing the pharmaceutical landscape.
SCI Pharmtech Inc is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in key markets, including the United States, Europe, Asia, and more. This diverse geographical reach allows SCI Pharmtech Inc to tap into various market opportunities, expand its customer base, and enhance international collaborations. The company's strategic focus on international expansion enables it to capitalize on emerging markets and establish long-term relationships with clients and partners across different countries and regions.
SCI Pharmtech Inc represents a set of core values and a strong corporate philosophy that guides its operations. The company is known for its commitment to excellence, innovation, and customer satisfaction. SCI Pharmtech Inc strives to deliver high-quality products and services that meet the evolving needs of its clients. With a focus on research and development, the company aims to stay at the forefront of the pharmaceutical industry. By fostering a collaborative and ethical work environment, SCI Pharmtech Inc promotes integrity, transparency, and social responsibility. Overall, SCI Pharmtech Inc is dedicated to creating value and making a positive impact in the pharmaceutical sector.
Analysts currently set an average price target of 77.97 TWD for the SCI Pharmtech stock (median: 77.97 TWD), implying +43.3 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the SCI Pharmtech stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect SCI Pharmtech to generate revenue of 1.41 B TWD and earnings per share of 0.97 TWD.
Converted at the current exchange rate, the SCI Pharmtech share trades at 1.52 EUR (54.40 TWD).
The SCI Pharmtech share (4119.TW) is listed on 1 stock exchanges, including: TWSE (Taiwan) (4119.TW).
SCI Pharmtech Inc is a leading company in the pharmaceutical industry, offering a wide range of products and services. The company focuses on the development, manufacturing, and marketing of innovative drugs and active ingredients and has become a key player in the industry. The company has several divisions that focus on the development and manufacturing of pharmaceutical products, formulation services, and customized contract research and development. The products they offer include solid, liquid, and semi-solid oral dosage forms, injections, immunologicals, and biologics. The company also offers customized services, including contract research and development, manufacturing process validation, and method development. Their goal is to provide their customers with a comprehensive range of services to accelerate their research and development processes and bring their drugs to market faster. SCI Pharmtech has also built a strong presence in Asia and Europe to promote its reach and growth. The company has subsidiaries in India and China and also has partnerships with various distribution partners in Europe and Asia. SCI Pharmtech's business model is based on the development of innovative drugs and active ingredients that meet customer requirements. The company invests in research and development to develop new technologies and processes that improve its manufacturing processes and meet customer needs. SCI Pharmtech also operates a comprehensive quality management system to ensure that all products and services meet the highest quality standards. The company has received a variety of certificates and awards that highlight its expertise and commitment to excellence in the industry. The company also has a strong culture of innovation, which allows it to develop industry-leading solutions and products. Through its research and development, the company strives to find solutions to critical challenges in the pharmaceutical industry and create innovative treatment options for existing and future diseases. Overall, SCI Pharmtech's business model is focused on providing innovative products and services to solve customer challenges. With its comprehensive range of products and services and its presence in Asia and Europe, the company has established itself as a trusted partner in the pharmaceutical industry.
The expected revenue of SCI Pharmtech is 1.41 B TWD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of SCI Pharmtech is 116.40 M TWD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of SCI Pharmtech is currently 56.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SCI Pharmtech stock.
The price-to-sales ratio (P/S) of SCI Pharmtech is currently 4.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SCI Pharmtech stock.
The Eulerpool Quality Score for SCI Pharmtech is 2/10.
The ISIN of SCI Pharmtech is TW0004119003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of SCI Pharmtech is 4119.TW. The ticker symbol is used to trade SCI Pharmtech shares on the stock exchange.
SCI Pharmtech stock
SCI Pharmtech Peer Group
SCI Pharmtech Ticker
SCI Pharmtech FIGI
All fundamentals and in-depth analysis of SCI Pharmtech
Our stock analysis for SCI Pharmtech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SCI Pharmtech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.